Schmidt et al., 2018 - Google Patents
A pilot study to non-invasively track PIK3CA mutation in head and neck cancerSchmidt et al., 2018
View HTML- Document ID
- 17497507263982954497
- Author
- Schmidt H
- Kulasinghe A
- Allcock R
- Tan L
- Mokany E
- Kenny L
- Punyadeera C
- Publication year
- Publication venue
- Diagnostics
External Links
Snippet
Background: PIK3CA pathways are the most frequently mutated oncogenic pathway in head and neck squamous cell carcinoma (HNSCC), including virally driven HNCs. PIK3CA is involved in the PI3K-PTEN-mTOR signalling pathway. PIK3CA has been implicated in …
- 230000035772 mutation 0 title abstract description 49
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/01—Social networking
Similar Documents
Publication | Publication Date | Title |
---|---|---|
McNamara et al. | Emerging biomarkers in glioblastoma | |
Ferlazzo et al. | Influence of MTHFR genetic background on p16 and MGMT methylation in oral squamous cell cancer | |
Ulivi et al. | Peripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLC | |
Moss et al. | Utility of circulating tumor DNA for detection and monitoring of endometrial cancer recurrence and progression | |
Schmidt et al. | A pilot study to non-invasively track PIK3CA mutation in head and neck cancer | |
Mitchell et al. | Evaluation of methylation biomarkers for detection of circulating tumor DNA and application to colorectal cancer | |
Nassar et al. | Circulating miRNA as biomarkers for colorectal cancer diagnosis and liver metastasis | |
Shi et al. | Frequent gene amplification predicts poor prognosis in gastric cancer | |
Miremami et al. | The promise of novel molecular markers in bladder cancer | |
Lin et al. | Circulating miRNAs act as diagnostic biomarkers for bladder cancer in urine | |
Gullo et al. | The transcriptomic landscape of gastric cancer: insights into Epstein-Barr virus infected and microsatellite unstable tumors | |
Nakamura et al. | Circulating microRNA panel as a potential novel biomarker for oral squamous cell carcinoma diagnosis | |
Pons-Belda et al. | Can circulating tumor DNA support a successful screening test for early cancer detection? The Grail paradigm | |
Lamy et al. | Mass spectrometry as a highly sensitive method for specific circulating tumor DNA analysis in NSCLC: a comparison study | |
Bjerre et al. | Epigenetic analysis of circulating tumor DNA in localized and metastatic prostate cancer: evaluation of clinical biomarker potential | |
Jaworski et al. | Circulating cell-free tumour DNA for early detection of pancreatic cancer | |
Adam-Artigues et al. | Identification of a two-microRNA signature in plasma as a novel biomarker for very early diagnosis of breast cancer | |
Carrasco et al. | Cell-free DNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer | |
Gianni et al. | Cell-free DNA fragmentomics: a promising biomarker for diagnosis, prognosis and prediction of response in breast Cancer | |
Keup et al. | Multimodal targeted deep sequencing of circulating tumor cells and matched cell-free DNA provides a more comprehensive tool to identify therapeutic targets in metastatic breast cancer patients | |
Fernandes et al. | Liquid biopsy for disease monitoring in non-small cell lung cancer: The link between biology and the clinic | |
Simarro et al. | Development, implementation and assessment of molecular diagnostics by next generation sequencing in personalized treatment of cancer: experience of a public reference healthcare hospital | |
Ntzifa et al. | DNA methylation analysis in plasma cell-free DNA and paired CTCs of NSCLC patients before and after osimertinib treatment | |
Kumaki et al. | Comprehensive genomic profiling of circulating cell-free DNA distinguishes focal MET amplification from aneuploidy in diverse advanced cancers | |
Cheng et al. | Systemic investigation identifying salivary miR-196b as a promising biomarker for early detection of head-neck cancer and oral precancer lesions |